|Hosted on behalf of the European Commission|
|EudraCT step-by-step guide|
|Tutorials on posting results|
|User manual and training|
|Frequently asked questions|
|National competent authorities|
|EU Clinical Trials Register|
|Need Help? Contact us!|
Welcome to the EudraCT public home page
EudraCT (European Union Drug Regulating Authorities Clinical Trials Database) is the database for all interventional clinical trials on medicinal products submitted to the National Competent Authorities (NCAs) of the European Union (EU)/European Economic Area (EEA) from 1 May 2004 until 30 January 2023 under Directive 2001/20/EC, as well as for all trials conducted outside of the EEA that are part of a Paediatric Investigation Plan (PIP) and/or are conducted under Article 45 or 46 of Regulation (EC) No 1901/2006. Most of the protocol and results information of EudraCT trials is made publicly available through the European Union Clinical Trials Register (see Frequently Asked Questions).
As of 31 January 2023, all initial clinical trial applications in the European Union (EU)/European Economic Area (EEA) must be submitted through the Clinical Trials Information System.
The EudraCT step-by-step guide, the use of the EudraCT database is now limited to:
Sponsors must transition their trials to CTIS in case:
In case of a multi-country trial, sponsors should ensure the harmonisation of their clinical trial under the Directive through EudraCT, prior to transitioning their trial to CTIS: see Clinical Trials Regulation Q&A section 11.
Clinical Trial Application recommendation: sponsors are recommended to include a functional contact point in section B.5.6 of the Clinical Trial Application/third country file, rather than details of one "person", which would require more frequent updates.
Requirement to provide results: sponsors are required to post EudraCT trials' results as per Joint Letter by the European Commission, EMA and HMA
CTIS: Clinical Trial Regulation, training material, homepage, legislation
As of 31 January 2023, all initial trial applications in the European Union (EU)/European Economic Area (EEA) must be submitted through CTIS. In case a new EU/EEA-country needs to be added to a EudraCT trial, the EudraCT trial needs to be transitioned to CTIS first: please refer to Clinical Trials Regulation Q&A section 11 for more information.
The EudraCT website has been affected by unexpected SPOR downtimes, which prevent users from performing usual functionalities, such as the uploading of an XML file. Update 24Feb2023: this issue is now solved; however, a few users have reported that they do not see their trials listed in 'your page', in order to post results. We encourage users to report this, in case they are affected, to allow a better investigation and resolution by our IT.
Users have reported issues with filling in section H of the EU/EEA CTA for protocol amendments and with the generation of EudraCT numbers for third country files. Our IT is currently working on this, we thank you very much for your patience. Update 14Feb2023: this issue is now solved
After implementing a system upgrade, on 02-02-2023 the EudraCT database experienced issues with results functionalities, which are now solved. We apologise for any inconvenience caused and we thank you for your patience.
The Clinical Trial Regulation is now mandatory for all initial EU/EEA clinical trial applications. The EudraCT website has been amended accordingly.
The EMA will be closed for public holidays until 03/01/2023 included. All requests submitted to the EudraCT team after 21/12/2022 will be processed from 04/01/2023. This includes Service Now queries, emails to EudraCT_notification@ema.europa.eu and requests for assignments to trials for the purpose of posting results. We thank you for your understanding and we encourage you to refer to the Frequently Asked Questions in the meantime.
EudraCT and EU CTR experienced several unexpected downtimes recently. Both websites are now operational and users can access them. We apologise for any inconvenience caused and we thank you for your patience.
Due to essential maintenance, the EudraCT website will have a downtime this evening between 6 pm and 8 pm (CET). We apologise for this inconvenience and we thank you very much for your patience.
Sponsors of clinical trials on COVID-19 are reminded to include the term "COVID-19" in the title of their trial (section A.3 of the CTA). Sponsors are also reminded of the importance of timely reporting of SAEs (Serious Adverse Events) and of SUSARs (Suspected Unexpected Serious Adverse Reactions) to the competent authorities, in order to protect the safety of the participants. In addition, we encourage sponsors of COVID-19 trials to post the relevant results as soon as it is feasible, also before the deadline.
Users have reported issues with uploading CTA XML files on EudraCT. Our IT is currently working on this, we thank you very much for your understanding and patience. Update 21Nov2022: this issue is now solved.
Kindly note that the EMA Service Desk has changed to ServiceNow and can be accessed via https://support.ema.europa.eu/esc. If you cannot access through this portal, please report your issue or ask your question through using the email address EudraCT_notification@ema.europa.eu. We thank you very much for your collaboration.
Due to essential maintenance of SPOR, the EudraCT website may experience momentary service losses on 3 and 4 September 2022. We apologise for this inconvenience and we thank you very much for your patience.
A considerable amount of clinical trials are currently marked as "ongoing" in the EudraCT database. In view of the upcoming transition of trials to CTIS, sponsors are encouraged to verify whether the correct status of their trials is reported on EU CTR. An end of trial form needs to be submitted to National Competent Authorities for the trials that should be marked as “completed” or “prematurely ended”. In addition, sponsors are requested to post results of these trials as per European Commission guideline 2012/C 302/03: to know how to post results visit Tutorials on posting results. For questions, refer to Contact us.
Following the issuing of the Joint Letter by the European Commission, EMA and HMA, National Competent Authorities and European Medicines Agency have sent reminders to sponsors who were not compliant with the European Commission guideline on results posting. Thanks to these reminders, the percentage of posted results substantially increased. However, for some trials the reminders were not successful: detailed lists of these trials can be found here.
Following the European Commission's Guidance on results postings, the European Medicines Agency and National Competent Authorities sent rounds of notifications in order to remind sponsors of their responsibilities as regards posting clinical trial results in EudraCT. In an attempt to reach sponsors who have not uploaded results yet, round of reminders are now being sent to email addresses stored not only in EudraCT, but also in other databases, such as the EMA Eudra Common Directory (results user roles list), EudraVigilance, SPOR and Art. 57 database.
Previous news can be found here
For the UK, as of 1.1.2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI.